73 results about "Disease biomarker" patented technology

The invention discloses a metabonomics data batch correction method based on multi-kernel learning, and belongs to the cross technical field of bioinformatics and analytical chemistry. According to the method, the multi-kernel learning technology is utilized, the advantages of different kernel functions are fused in a self-adaptive mode, a model conforming to data reality is constructed, complex drift characteristics of metabolite signals are accurately captured, and efficient and accurate normalization processing of metabonomics data is achieved. Compared with traditional data standardization methods such as SVR and LOESS, the method has the advantages that the performance is excellent in the aspect of reducing the metabolite peak intensity variability, and the data stability is remarkably improved. In the subsequent multivariate statistical analysis, the classification accuracy is greatly improved, the comparability among different batches of data is also remarkably enhanced, reliable data support can be provided for discovery of disease biomarkers, and the method plays a key role in large-scale metabonomics research.

A disease marker expression network reconstruction feature key point determination method belongs to the technical field of disease markers, and comprises the following steps: processing a to-be-detected tissue sample to obtain marker multi-dimensional data; performing wavelet decomposition on the marker multi-dimensional data to obtain a marker multi-scale coefficient, wherein the marker multi-scale coefficient comprises a reference component, a high-frequency component, an intermediate-frequency component and a low-frequency component; constructing a frequency domain incidence matrix based on the marker multi-scale coefficient, wherein the frequency domain incidence matrix represents the incidence intensity between different frequency components; constructing a network reconstruction model according to the frequency domain incidence matrix and multi-scale weights, wherein the multi-scale weights comprise a reference weight, a high-frequency weight, an intermediate-frequency weight and a low-frequency weight; the existing marker expression network reconstruction and key node identification method has some limitations, and the technical problem that the method for determining the reconstruction feature key points of the disease marker expression network in the prior art is not accurate enough is solved.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

The invention discloses an immunochromatography test strip based on a nano-robot as well as a preparation method and application thereof. The immunochromatography test strip comprises a bottom plate, and a sample pad, filter paper, a nitrocellulose membrane and absorbent paper which are sequentially overlapped and adhered to the bottom plate, when in use, an FPSN (at) Ab buffer solution is dropwise added on the surface of the sample pad; the FPSN (at) Ab buffer solution is prepared from Fe3O4 (at) mPDAamp; the preparation method comprises the following steps: preparing an mSiO2 (at) Nanozyme nano composite material and an antibody to be marked; the Fe3O4 (at) is mPDAamp; the mSiO2 (at) Nanozyme nano composite material is nano particles with an asymmetric structure, one end of the asymmetric structure is a core-shell structure, the core is Fe3O4, the shell is mesoporous polydopamine particles, the other end is rod-like mesoporous SiO2, and noble metal nano particles are loaded on the surfaces of Fe3O4 and mesoporous SiO2; according to the invention, the nano-robot is used as the probe to construct the immunochromatography test strip, so that the detection sensitivity and the detection speed of the test strip are improved, the binding efficiency between the probe and the to-be-detected object is optimized, and the problem that in the prior art, accurate detection of disease markers is difficult to realize under the conditions of small sample size and low concentration is solved.

An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.

Deep learning methods and systems for detecting biomarkers within optical coherence tomography volumes using such deep learning methods and systems are provided. Embodiments predict the presence or absence of clinically useful biomarkers in OCT images using deep neural networks. The lack of available training data for canonical deep learning approaches is overcome in embodiments by leveraging a large external dataset consisting of foveal scans using transfer learning. Embodiments represent the three-dimensional OCT volume by “tiling” each slice into a single two dimensional image, and adding an additional component to encourage the network to consider local spatial structure. Methods and systems, according to embodiments are able to identify the presence or absence of AMD-related biomarkers on par with clinicians. Beyond identifying biomarkers, additional models could be trained, according to embodiments, to predict the progression of these biomarkers over time.

The invention provides a disease marker binding pocket identification method, and belongs to the technical field of disease marker binding pockets, and the method comprises the following steps: firstly, constructing a simulation system containing a disease marker, and carrying out 100-500ns molecular dynamics simulation; a conformation change track is collected and subjected to normalization processing; carrying out decomposition calculation on the sampled conformation, and analyzing a conformation cluster with relatively high frequency; calculating structural parameters of amino acid residues, and screening a region with relatively high flexibility as a potential binding site; analyzing the solvent accessibility and electrostatic characteristics of the sites; identifying a temporary binding pocket through the water molecule distribution density; performing principal component analysis to extract a conformation change mode; constructing an amino acid residue interaction network, and screening a stable binding pocket based on indexes such as binding free energy, conformational stability and pocket comprehensive performance evaluation; the method solves the problem that most existing methods only consider static structural characteristics of molecules and neglect the influence of dynamic change of protein conformation on binding pocket formation.

The application discloses a preparation method of a VP@UiO-66-NH2 / Ag NPs composite SERS chip and application thereof in A beta protein detection, and is characterized by comprising the following steps: synthesizing a VP-graphite paper base by a chemical vapor transport method on a surface of a graphite paper to obtain a VP-graphite paper base; synthesizing a UiO-66-NH2 layer on the surface of the VP-graphite paper base by a solvothermal method to obtain a VP@UiO-66-NH2 composite base; and finally, placing the composite base in an ion sputtering instrument, uniformly sputtering silver nanoparticles on the surface of the composite base, taking out the composite base, and obtaining the VP@UiO-66-NH2 / Ag NPs composite SERS chip, wherein the VP@UiO-66-NH2 / Ag NPs composite SERS chip has the advantages of high sensitivity, good stability and uniformity, controllable preparation process, low cost, application in Alzheimer's disease biomarker detection, high specificity in identification and quantitative analysis of A beta 40 and A beta 42 proteins, fast response and good stability.

This invention discloses a method for preparing HVC NPs for the diagnosis and treatment of Parkinson's disease and their applications. The probe HV in the HVC NPs responds to H2O2 and viscosity, utilizing near-infrared fluorescence imaging capabilities to achieve real-time monitoring of Parkinson's disease biomarkers, helping us better understand the occurrence and development of Parkinson's disease. With the assistance of RVG29, the HVC NPs effectively cross the blood-brain barrier. The curcumin within them can reduce cell apoptosis, lower oxidative stress levels, scavenge excess reactive oxygen species, combat inflammation, and reduce α-synuclein aggregation, demonstrating effective anti-Parkinson's disease effects at the cellular and experimental animal levels. This nanomaterial provides a new strategy for integrated research on the diagnosis and treatment of Parkinson's disease.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

To provide a pretreatment method of a specimen for accurately and simply performing quantification of a biomarker protein by preventing aggregation of a disease biomarker protein in the specimen or adsorption thereof to a container.SOLUTION: A pretreatment method of a specimen containing an aggregation biomarker protein, includes a step of mixing the specimen with sodium dodecyl sulfate (SDS). A quantification method of an aggregation biomarker protein in a specimen, includes the steps of: mixing the specimen with sodium dodecyl sulfate (SDS); and after the mixing step, specifically detecting and quantifying the biomarker protein in the specimen.SELECTED DRAWING: None

Provided herein is technology relating to obtaining and testing biological samples for disease biomarkers and particularly, but not exclusively, to hydrogel-coated microneedles, arrays of hydrogel-coated microneedles, and related methods of making stellate microcolumns and hydrogel-coated microneedles and using the hydrogel-coated microneedles for capturing exosomes from subject tissues for diagnosing diseases such as cancer.

The present invention relates to a biomarker HLA-DOA for sepsis-related diseases and a use thereof. The present invention provides a use of HLA-DOA or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in a subject.

The invention is suitable for the technical field of bioengineering, and provides a CRISPR Cas13a mutant, and a coding gene, an expression plasmid, a protein expression system and application thereof. Compared with the wild type CRISPR Cas13a (Cas13a-WT), the amino acid residue at the 967th site of the amino acid sequence of the CRISPR Cas13a mutant Cas13a-Y967E is mutated into an amino acid which keeps the specificity of the amino acid sequence and has improved RNA (Ribonucleic Acid) shearing activity. The amino acid sequences of the Cas13a-WT and the Cas13a-Y967E are respectively as shown in SEQ ID NO. 1 and SEQ ID NO. 2, and the Cas13a-WT and the The RNA shearing activity of the Cas13a-Y967E is remarkably improved, the specificity of the Cas13a-Y967E is kept, target pathogens or disease biomarkers can be recognized and detected more accurately and efficiently in the fields of pathogen detection, disease diagnosis and treatment and the like, and missing detection and false detection are reduced.

This invention discloses a filter coating composition for fluorescence detection and its preparation method, relating to the fields of optical materials and biodetection technology. The composition is formulated by compounding optical functional powders, polymer substrates, dispersants, and additives in specific proportions, exhibiting high transmittance, narrow wavelength selectivity, excellent weather resistance and mechanical stability. It can accurately filter excitation light and stray light, improving the sensitivity and specificity of fluorescence detection. The filter coating composition and its preparation method for fluorescence detection also provide a simple, cost-effective manufacturing process suitable for large-scale production, particularly applicable to gene sequencing and immunochemistry. It addresses the problems of poor wavelength selectivity, weak stability, and high cost associated with traditional filters, making it suitable for fluorescence detection scenarios such as Alzheimer's disease biomarkers. Balancing accuracy, stability, and economy, it has broad application prospects in the field of in vitro diagnostic reagents.

The present invention relates to methods for obtaining a biological sample with improved quality. It encompasses the identification of markers or proteins in a biological sample that are altered due to variations in sample collection, handling, and processing. The method can also be used to correct variations in the measurement results of disease biomarkers. Additionally, if it is determined that the sample collection method is inconsistent with a predetermined protocol, the method can allow for the rejection of a sample or group of samples as needed. Other advantages useful to those skilled in the art are described herein.

The invention provides an early biomarker for cognitive impairment of Parkinson's disease, application of the early biomarker and an intelligent analysis system for Parkinson's disease. The biomarker is a GALC gene. The intelligent analysis system for the early biomarkers of the cognitive impairment of the Parkinson's disease comprises a data integration module and a data analysis module. The data integration module is used for acquiring a gene detection result, an olfactory test score and neuroimaging data of the Parkinson's disease biomarker; and the data analysis module is used for analyzing the influence of gene variation of the Parkinson's disease biomarker on olfactory dysfunction and cognitive decline of the Parkinson's disease patient by adopting a structural equation model SEM based on the multi-modal data set. According to the application, through confluence analysis of multi-modal data, by combining genetics, neuroimaging and clinical evaluation, the rs8005172 site variation of the GALC gene is taken as an early biomarker of cognitive impairment of Parkinson's disease, so that PD patients with high cognitive decline risk can be accurately identified.

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.

Systems and methods for detecting a disease biomarker in a subject are provided. In some embodiments, a system includes an oral device configured to be positioned within a subject's mouth, and a hydrogel carried by the oral device, the hydrogel including a polymer and a fluorescent moiety. When the oral device is positioned within the subject's mouth, the hydrogel can be configured to release the fluorescent moiety into the subject's mouth, and the fluorescent moiety can be configured to label a disease biomarker present in the subject's mouth.

The invention relates to the field of instant detection of disease diagnosis, and discloses an Alzheimer's disease marker detection method based on enzymatic fluorescent silicon nanodots, which comprises the following steps: enriching a target marker by using a magnetic capture probe and forming an enzyme-labeled immune sandwich compound; adding a substrate, and performing in-situ induction by using ascorbic acid generated by enzymatic reaction to generate fluorescent silicon nanodots or inhibit chromogenic reaction; the method comprises the following steps: acquiring a time sequence image of a reaction system, eliminating interference pixels by utilizing HSV color space conversion and a chromaticity characteristic mask algorithm, calculating a reaction kinetics rate, and combining a standard curve to realize quantitative analysis. By introducing an alkaline phosphatase-induced cascade reaction system and utilizing an enzymolysis product ascorbic acid to generate fluorescent silicon nanodots in situ or regulate and control the oxidation-reduction state of TMB (Tetramethylbenzidine), high-sensitivity detection of Tau protein and Abeta-42 protein is realized, so that the detection sensitivity of low-concentration Alzheimer's disease markers is improved.

The present invention relates to a sepsis-related disease biomarker HLA-DQA and the use thereof. Provided in the present invention is the use of HLA-DQA or an active fragment and functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction, and / or treatment regimen selection of a sepsis-related disease in a subject.

Set forth herein are methods useful for identifying disease biomarkers, particularly for diseases such as clear cell renal cell carcinoma (ccRCC). In some examples, the methods set forth herein are useful for monitoring the prognosis of patients having disease such as ccRCC.

The invention provides a probe system and method for detecting AKI-related miRNA based on primer exchange reaction and G-quadruplex, and belongs to the technical field of molecular probe fluorescence sensing. Target miRNA-driven PER amplification, PER product-induced G tetramer conformational change and G-Quadruplex-ThT signal'lightening 'mechanism are organically combined to detect the AKI-related miRNA. A low-background label-free signal amplification system is constructed for accurate detection of target miRNA, has the characteristics of high sensitivity, strong specificity, simplicity in operation and the like, and still keeps good performance in an actual sample. Besides, by designing the dumbbell-shaped hairpin probe HP, specific detection of different targets can be realized, and the establishment of the technical platform provides a new method for research and development of a kit for simultaneously realizing rapid detection of disease biomarkers such as small molecules, nucleic acid, protein and the like.

Methods for producing an RNA vaccine for a subject with a disease and producing a database of disease biomarkers are provided. Methods for discovering disease biomarkers and diagnosing disease are also provided. The present invention enables frequent monitoring of subjects and adjustment of treatment. The present invention also provides methods for preparing processed nucleic acid samples with a more uniform distribution of sequences, which can be more readily analysed. The methods may be combined to further improve the ability to produce RNA vaccines and discover disease biomarkers.

The invention discloses a biomarker for diagnosing Alzheimer's disease as well as a screening method and application thereof, relates to the technical field of biomarkers for Alzheimer's disease, and aims to solve the technical problems that the Alzheimer's disease lacks dynamic pathological monitoring indexes and stereoisomeric modification is difficult to systematically detect. According to the invention, the stereoisomeric modification level of peptide fragments KLDLSNVQSK and AKTDHGAEIVYK is used as the core biomarker for the first time, the modification level is remarkably related to the Braak staging of AD, and a detection method and a combined diagnosis model containing the marker are provided. A novel molecular target with high correlation and dynamic monitoring potential is provided for AD, the model diagnosis precision is remarkably improved, and a brand new solution is provided for disease mechanism research and drug development.

To enhance prediction accuracy of a therapy-biomarker unknown relation.SOLUTION: An information processing system predicts a therapy-biomarker unknown binary relation from a therapy-biomarker-disease known triadic relation. The information processing system is configured to generate a bipartite graph by diseases expressing the-therapy-biomarker binary relation for each disease from the known triadic relation; calculate, from the bipartite graph by diseases, similarity among therapies by diseases of the therapies, similarity among disease transverse type therapies of the therapies, similarity among biomarkers by diseases of the biomarkers, and similarity among disease transverse type biomarkers of the biomarkers; and calculate and output a prediction score by diseases of an unknown edge, and a disease transverse prediction score.SELECTED DRAWING: Figure 1

The high incidence of Alzheimer's disease caused by global aging has become an important social problem. The blood screening has the characteristics of noninvasive property and low cost, so that the blood screening becomes the most promising early diagnosis measure for the Alzheimer's disease. However, the practical application of Alzheimer's blood screening faces challenge. Firstly, due to the blood brain barrier, the concentration of the Alzheimer's disease biomarker in blood is far lower than that of cerebrospinal fluid; and secondly, the specificity of a single biomarker is relatively low. In the invention, a 3D DNA (Deoxyribose Nucleic Acid) walking machine based on DNAzyme is provided, and the 3D DNA walking machine is used for simultaneously and sensitively detecting the five miRNA biomarkers related to the Alzheimer's disease in a multiple manner, namely hsa-miR-125b, hsa-miR-342-3p, hsa-miR-29b, hsa-miR-191-5p and hsa-miR-7d-5. Efficient amplification is achieved through the walking machine, and released 89Y, 165 Ho, 139La, 140 Ce and 159Tb are subjected to multiple sensitive detection without spectral line overlapping through an element mass spectrometry method. The method is successfully applied to a human serum sample. The metal isotope strategy is expected to play an important role in early diagnosis and intervention of the Alzheimer's disease.

This invention provides a sample pretreatment kit and its application for the simultaneous detection of Aβ40, Aβ42, and lencanezumab, belonging to the field of biodetection technology. The kit includes: mixed magnetic beads, internal standard solution, trypsin digestion solution, enzyme digestion enhancer, and ammonia; the mixed magnetic beads are composed of protein A magnetic beads and streptavidin magnetic beads; the internal standard solution is composed of… 15 N-labeled Aβ40, 15 This kit consists of N-labeled Aβ42 and lencanezumab internal standard peptides. The pretreatment kit eliminates the need for anti-IgG1 antibodies, requiring only Protein A for detection, thus shortening sample processing time, greatly simplifying the sample handling process, and increasing throughput. The kit can simultaneously detect Aβ40, Aβ42, and lencanezumab, providing more reliable data support for clinical diagnosis and treatment efficacy evaluation, and significantly promoting the development of companion detection technologies for Alzheimer's disease biomarkers and therapeutic drugs.

This invention discloses a method and application for detecting N-glycans based on in-gel enzymatic digestion and electrophoresis. The method includes the following steps: separating glycoprotein samples and cutting target bands by gel electrophoresis; decolorizing and dehydrating the target glycoprotein particles; adding enzyme solution for direct enzymatic release of N-glycans within the gel; transferring the enzyme digestion solution after sonication, drying, and labeling the N-glycan sample; and finally, separating, detecting, and analyzing the N-glycans using capillary electrophoresis. This invention innovatively combines in-gel enzymatic digestion with capillary electrophoresis, avoiding the complex sample transfer and pretreatment steps of traditional methods, significantly simplifying the operation process, reducing sample loss, and making it particularly suitable for the efficient detection of low-abundance N-glycans. This method features high sensitivity, high resolution, and high throughput, and can accurately analyze N-glycans in complex biological samples, with wide applications in disease biomarker screening, clinical diagnosis, and glycomics research.